Annamycin Phase III AML trial reports triple remission rate
The Phase III AML trial for an annamycin-based therapy reported remission rates three times higher than control, with no cardiotoxicity reported.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.